Numinus Clinics

Supporting & empowering the journey to wellness.

We look forward to helping practitioners develop and deliver the highest quality of care to patients, centred around psychedelic-assisted psychotherapy. By offering Numinus-owned training, resources and facilities, we proudly partner with medical leaders across psychedelic and mental health programming as they help patients achieve their wellness goals.

With the upcoming close of our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus will be able to support practitioners across 4 clinic locations in Montreal and Vancouver.

We support three pathways for exploring psychedelic-assisted psychotherapy:

Ketamine-assisted psychotherapy

Practitioners at Mindspace in Montreal now offer KAP, which can be prescribed to address treatment-resistant depression.

Special Access for psilocybin & MDMA

Pending approval of regulatory change, Numinus intends to support practitioners in helping their patients obtain Special Access to psychedelic-assisted therapies for a range of conditions and delivering these through the clinics in both Vancouver and Montreal.

Health Canada has posted its Notice of Intent, subject to public consultation, to revise its Special Access Programme to allow legal access to psilocybin and MDMA outside of clinical trials, while the substances await formal approvals.

Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of the healthcare system.

Through a formal briefing note to Minister Patty Hajdu, Numinus provided research evidence and clinical recommendations to help inform Health Canada’s decision on SAP. See the note here.

Compassionate access trials for psilocybin & MDMA

Numinus is undertaking two compassionate access clinical trials, which will be conducted by our medical team in our Vancouver clinic. Both trials will be open to Canadian participants.

  1. MDMA-assisted psychotherapy for PTSD, in collaboration with psychedelic research and advocacy pioneer MAPS (Multidisciplinary Association for Psychedelic Studies)
  2. Psilocybin-assisted psychotherapy for substance use disorders


To learn more about clinical services to be offered pending acquisition close, visit Mindspace. To receive more information on Special Access and our trials, sign up here.